Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluorescence Guided Focal Cortical Dysplasia Surgery
NCT07657975Phase 2Not yet recruiting
- Sponsor
- Hospices Civils de Lyon
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 2 trial of 5-aminolevulinic acid in epilepsy, focal cortical dysplasia (FCD), sponsored by Hospices Civils de Lyon. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
5-aminolevulinic acid
03
Conditions
epilepsyfocal cortical dysplasia (FCD)
Beyond the preview
Go deeper on NCT07657975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07657975.